CPT1A is highly expressed in prostate cancer (124), nasopharyngeal carcinoma (125, 126), glioblastoma (127), etc. Inhibition of CPT1A significantly inhibits tumor growth, improves survival, and increases the sensitivity of nasopharyngeal carcinoma to radiotherapy (125). Here, CPT1A is linked to glioblastoma.